Craft

Amoy Diagnostics

Stock Price

¥24.5

2024-10-29

Market Capitalization

¥9.5 B

2024-10-29

Revenue

¥1.2 B

FY, 2025

Amoy Diagnostics Summary

Company Summary

Overview
Amoy Diagnostics (AmoyDx, 厦门艾德生物医药科技股份有限公司) is a company that provides molecular diagnostic products and services for oncology precision medicine. It uses technology platforms including next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH) to provide single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems. The company serves healthcare providers, academic institutions, and pharmaceutical businesses.
Type
Public
Status
Active
Founded
2008
HQ
Xiamen, CN | view all locations
Website
https://amoydiagnostics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Li-Mou Zheng, Chairman

    • Frank Ron Zheng, Director and Deputy General manager

      • David Guowei Wang, Director

        Operating MetricsView all

        Patents (Domestic)

        55
        22.2%

        H1, 2022

        Medical Device Registration Certificates

        24
        4.3%

        H1, 2022

        Medical Institutions Covered

        500

        H1, 2022

        LocationsView all

        2 locations detected

        • Xiamen, Fujian Sheng HQ

          China

          39 Dingshan Road, Haicang District

        • Singapore

          Singapore

          2 Science Park Drive, Ascent, #01-08

        Amoy Diagnostics Financials

        Summary Financials

        Revenue (Q1, 2026)
        ¥257.3M
        Gross profit (Q1, 2026)
        ¥211.7M
        Net income (Q1, 2026)
        ¥85.2M
        Cash (Q1, 2026)
        ¥1.1B
        EBIT (Q1, 2026)
        ¥103.0M
        Enterprise value
        $8.6B

        Footer menu